We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A new study in France has found that hydroxychloroquine provides no benefit for COVID-19 patients, adding to the growing evidence that the anti-malaria drug has little value as a coronavirus treatment. Read More
President Trump on Friday outlined a strikingly ambitious plan to have a COVID-19 vaccine approved by the FDA and starting to be deployed by year’s end. Read More
Previous research in laboratory settings and animal studies suggest that interferon-lambda may help control viruses that cause respiratory illnesses, such as influenza and SARS. Read More
As a growing number of studies raise alarms about using hydroxychloroquine to treat COVID-19, the National Institutes of Health (NIH) is starting a large clinical trial to evaluate the drug in combination with the antibiotic azithromycin. Read More
The first phase will evaluate whether a seven-day course of hydroxychloroquine can reduce the severity of symptoms and help avoid hospital admission. Read More
The World Health Organization (WHO) said this week that “potentially positive data” is coming out of early clinical trials of COVID-19 treatments, but it declined to name the specific drugs showing promise. Read More
Oxford University has launched a clinical trial testing existing drugs, including hydroxychloroquine and azithromycin, as preventative COVID-19 treatments in older patients. Read More
After Gilead Sciences’ remdesivir was approved for emergency use on COVID-19 patients, a number of other trials have gotten underway to test the antiviral’s benefits in combination with other drugs. Read More